CN103966351A - CST1mRNA和CST4mRNA或其编码的蛋白质在制备肾癌标志物中的应用及其试剂盒 - Google Patents
CST1mRNA和CST4mRNA或其编码的蛋白质在制备肾癌标志物中的应用及其试剂盒 Download PDFInfo
- Publication number
- CN103966351A CN103966351A CN201410235186.9A CN201410235186A CN103966351A CN 103966351 A CN103966351 A CN 103966351A CN 201410235186 A CN201410235186 A CN 201410235186A CN 103966351 A CN103966351 A CN 103966351A
- Authority
- CN
- China
- Prior art keywords
- seq
- cystatin
- cst4mrna
- cst1mrna
- diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010038389 Renal cancer Diseases 0.000 title abstract description 19
- 208000008839 Kidney Neoplasms Diseases 0.000 title abstract description 6
- 201000010982 kidney cancer Diseases 0.000 title abstract description 6
- 108090000623 proteins and genes Proteins 0.000 title abstract description 6
- 102000004169 proteins and genes Human genes 0.000 title abstract description 5
- 238000001514 detection method Methods 0.000 claims abstract description 79
- 238000003745 diagnosis Methods 0.000 claims abstract description 32
- 238000011156 evaluation Methods 0.000 claims abstract description 14
- 238000012544 monitoring process Methods 0.000 claims abstract description 10
- 102000018968 Salivary Cystatins Human genes 0.000 claims description 104
- 108010026774 Salivary Cystatins Proteins 0.000 claims description 104
- 239000000523 sample Substances 0.000 claims description 52
- 210000003734 kidney Anatomy 0.000 claims description 50
- 238000012546 transfer Methods 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 15
- 230000005291 magnetic effect Effects 0.000 claims description 14
- 239000011324 bead Substances 0.000 claims description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 4
- 239000002532 enzyme inhibitor Substances 0.000 claims description 4
- 108091092562 ribozyme Proteins 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 238000011282 treatment Methods 0.000 abstract description 35
- 210000002700 urine Anatomy 0.000 abstract description 26
- 238000000034 method Methods 0.000 abstract description 20
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 3
- 206010027476 Metastases Diseases 0.000 abstract description 2
- 230000009401 metastasis Effects 0.000 abstract description 2
- 238000005070 sampling Methods 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 abstract description 2
- 239000003550 marker Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 108050004038 cystatin Proteins 0.000 description 42
- 102000015833 Cystatin Human genes 0.000 description 41
- 208000006265 Renal cell carcinoma Diseases 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 13
- 201000010174 renal carcinoma Diseases 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 101100008568 Homo sapiens CST4 gene Proteins 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 102100034583 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 Human genes 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 101000590272 Homo sapiens 26S proteasome non-ATPase regulatory subunit 2 Proteins 0.000 description 9
- 101000848781 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 Proteins 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 101100062319 Homo sapiens CST1 gene Proteins 0.000 description 8
- 238000003759 clinical diagnosis Methods 0.000 description 8
- 239000013256 coordination polymer Substances 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 101150117578 RPN1 gene Proteins 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 101150031602 CST11 gene Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 101710103147 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 239000006148 magnetic separator Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100028007 Cystatin-SA Human genes 0.000 description 1
- 101710144510 Cysteine proteinase inhibitor Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- -1 hydroxy propyl Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
标准品编号 | 浓度(copy/μL) |
STD1 | 100000 |
STD2 | 10000 |
STD3 | 1000 |
STD4 | 100 |
标准品编号 | 浓度(copy/μL) |
STD1 | 100000 |
STD2 | 10000 |
STD3 | 1000 |
STD4 | 100 |
患者编号 | 治疗前后浓度变化百分比 | 临床评价 |
1 | 下降6% | 无效 |
2 | 升高5% | 疗效显著 |
3 | 降低69% | 改善 |
4 | 降低53% | 改善 |
5 | 升高9% | 无效 |
6 | 降低70% | 疗效显著 |
7 | 降低48% | 改善 |
8 | 降低40% | 无效 |
9 | 降低18% | 无效 |
10 | 降低35% | 改善 |
患者编号 | 6周 | 3个月 | 6个月 | 9个月 | 临床评价 |
1 | 0.13 | 0.15 | 0.11 | 0.10 | 无进展生存 |
2 | 0.26 | 0.42 | 0.58 | 0.77 | 转移复发 |
3 | 0.58 | 0.61 | 0.66 | 0.85 | 转移复发 |
4 | 0.39 | 0.45 | 0.50 | 0.55 | 无进展生存 |
5 | 0.41 | 0.33 | 0.55 | 0.65 | 无进展生存 |
6 | 0.24 | 0.26 | 0.29 | 0.27 | 无进展生存 |
患者编号 | 治疗前后浓度变化百分比 | 临床评价 |
1 | 下降41% | 改善 |
2 | 升高3% | 无效 |
3 | 升高7% | 无效 |
4 | 降低70% | 疗效显著 |
5 | 升高15% | 无效 |
6 | 降低50% | 改善 |
7 | 降低42% | 改善 |
8 | 降低60% | 改善 |
9 | 降低49% | 无效 |
10 | 降低90% | 疗效显著 |
患者编号 | 6周 | 3个月 | 6个月 | 9个月 | 临床评价 |
1 | 0.31 | 0.30 | 0.35 | 0.40 | 无进展生存 |
2 | 0.25 | 0.27 | 0.38 | 0.44 | 无进展生存 |
3 | 0.45 | 0.56 | 0.67 | 0.87 | 转移复发 |
4 | 0.43 | 0.43 | 0.37 | 0.56 | 无进展生存 |
5 | 0.32 | 0.41 | 0.59 | 0.71 | 转移复发 |
6 | 0.29 | 0.33 | 0.49 | 0.46 | 无进展生存 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410235186.9A CN103966351B (zh) | 2014-05-29 | 2014-05-29 | CST1mRNA和CST4mRNA或其编码的蛋白质在制备肾癌标志物中的应用及其试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410235186.9A CN103966351B (zh) | 2014-05-29 | 2014-05-29 | CST1mRNA和CST4mRNA或其编码的蛋白质在制备肾癌标志物中的应用及其试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103966351A true CN103966351A (zh) | 2014-08-06 |
CN103966351B CN103966351B (zh) | 2015-06-10 |
Family
ID=51236352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410235186.9A Active CN103966351B (zh) | 2014-05-29 | 2014-05-29 | CST1mRNA和CST4mRNA或其编码的蛋白质在制备肾癌标志物中的应用及其试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103966351B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105154581A (zh) * | 2015-10-27 | 2015-12-16 | 崔长友 | 一种非小细胞肺癌的诊断和预示方法和生物检测试剂盒 |
CN105349640A (zh) * | 2015-10-27 | 2016-02-24 | 杨廷稳 | 一种用于诊断和预示乳腺癌的生物标志物和检测试剂盒 |
CN106399527A (zh) * | 2016-10-14 | 2017-02-15 | 浙江大学 | 一种用于检测肾癌的引物组及检测方法 |
CN107688095A (zh) * | 2017-08-19 | 2018-02-13 | 杭州飞悦生物技术有限公司 | 检测人胱抑素sn的酶联免疫试剂盒及制备方法及检测方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101985651A (zh) * | 2010-04-30 | 2011-03-16 | 苏州工业园区为真生物医药科技有限公司 | 胃肠肿瘤诊断和预示的新分子标记 |
WO2013104102A1 (zh) * | 2012-01-09 | 2013-07-18 | 苏州工业园区为真生物医药科技有限公司 | 乳腺癌诊断和预示的标志物 |
CN103667444A (zh) * | 2013-09-29 | 2014-03-26 | 中山大学附属第三医院 | 一种与胰腺癌相关的肿瘤标记物及其应用 |
CN103740854A (zh) * | 2014-01-29 | 2014-04-23 | 中山大学附属第三医院 | 一种肿瘤标记物及其在制备结直肠癌诊断试剂中的应用 |
-
2014
- 2014-05-29 CN CN201410235186.9A patent/CN103966351B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101985651A (zh) * | 2010-04-30 | 2011-03-16 | 苏州工业园区为真生物医药科技有限公司 | 胃肠肿瘤诊断和预示的新分子标记 |
WO2013104102A1 (zh) * | 2012-01-09 | 2013-07-18 | 苏州工业园区为真生物医药科技有限公司 | 乳腺癌诊断和预示的标志物 |
CN103667444A (zh) * | 2013-09-29 | 2014-03-26 | 中山大学附属第三医院 | 一种与胰腺癌相关的肿瘤标记物及其应用 |
CN103740854A (zh) * | 2014-01-29 | 2014-04-23 | 中山大学附属第三医院 | 一种肿瘤标记物及其在制备结直肠癌诊断试剂中的应用 |
Non-Patent Citations (2)
Title |
---|
TURK V ET AL.: "Cystatins:biochemical and structural properties,and medical relevance", 《FRONT BIOSCI》, vol. 13, 1 May 2008 (2008-05-01), pages 5406 - 5420 * |
YONEDA K ET AL.: "Identification of cystatin SN as a novel tumor marker for colorectal cancer", 《INT J ONCOL》, vol. 35, no. 1, 31 July 2009 (2009-07-31), pages 33 - 40, XP002547543, DOI: 10.3892/ijo_00000310 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105154581A (zh) * | 2015-10-27 | 2015-12-16 | 崔长友 | 一种非小细胞肺癌的诊断和预示方法和生物检测试剂盒 |
CN105349640A (zh) * | 2015-10-27 | 2016-02-24 | 杨廷稳 | 一种用于诊断和预示乳腺癌的生物标志物和检测试剂盒 |
CN106399527A (zh) * | 2016-10-14 | 2017-02-15 | 浙江大学 | 一种用于检测肾癌的引物组及检测方法 |
CN107688095A (zh) * | 2017-08-19 | 2018-02-13 | 杭州飞悦生物技术有限公司 | 检测人胱抑素sn的酶联免疫试剂盒及制备方法及检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103966351B (zh) | 2015-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Smoczynski et al. | Routine brush cytology and fluorescence in situ hybridization for assessment of pancreatobiliary strictures | |
Sakurada et al. | Detection of dermcidin for sweat identification by real-time RT-PCR and ELISA | |
CN103966351B (zh) | CST1mRNA和CST4mRNA或其编码的蛋白质在制备肾癌标志物中的应用及其试剂盒 | |
CN103898205B (zh) | 半胱氨酸蛋白酶抑制剂sn的应用 | |
US9857375B2 (en) | Cancer marker and utilization thereof | |
CN105671181A (zh) | 用于检测肺癌的基因标志物、引物、探针及试剂盒 | |
CN109576370A (zh) | 用于膀胱癌诊断和复发监控的生物标志物及检测试剂盒 | |
CN104004840A (zh) | 用于早期筛查与诊断前列腺癌的试剂盒 | |
Gorish et al. | A correlation study of BK Polyoma Virus infection and prostate Cancer among Sudanese patients-immunofluorescence and molecular based case-control study | |
CN109371133A (zh) | 一组与胰腺癌相关的LncRNA分子标记物及其应用 | |
US9863952B2 (en) | Method for the diagnosis of higher- and lower-grade astrocytoma using biomarkers and diagnostic kit thereof | |
Wang et al. | Plasma expression of miRNA-21,− 214,− 34a, and-200a in patients with persistent HPV infection and cervical lesions | |
CN103940996B (zh) | Cystatin SN和AFP在制备诊断和预示肝癌标志物中的应用 | |
JP2023113877A (ja) | 膵がんの検出を補助する方法 | |
CN105154581A (zh) | 一种非小细胞肺癌的诊断和预示方法和生物检测试剂盒 | |
CN103966350B (zh) | CST1 mRNA和CST4 mRNA或其编码的蛋白质在制备尿道癌标志物中的应用及其试剂盒 | |
CN103966352B (zh) | Pca3、cst1和cst4在制备前列腺癌标志物中的应用及其试剂盒 | |
CN103966348B (zh) | CST1mRNA和CST4mRNA或其编码的蛋白质在制备膀胱癌标志物中的应用及其试剂盒 | |
CN104046685A (zh) | 用于胃癌的诊断和预后的表观遗传生物标志物adamts9 | |
CN103849683B (zh) | 前列腺癌尿液检测试剂盒及其应用 | |
CN110331208A (zh) | 分子靶标在肺腺癌联合诊断中的应用 | |
Komatsuda et al. | Serum procalcitonin levels in patients with myeloperoxidase-antineutrophil cytoplasmic antibodies-associated glomerulonephritis | |
CN105349640A (zh) | 一种用于诊断和预示乳腺癌的生物标志物和检测试剂盒 | |
CN101429540A (zh) | 实时定量pcr检测细胞周期蛋白b2基因表达的方法 | |
CN103901207B (zh) | Cystatin S和CA15-3在制备诊断和预示乳腺癌标志物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SUZHOU MICRO DIAG BIOMEDICINE CO., LTD. Free format text: FORMER OWNER: SHANGHAI DUWEI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20141103 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201507 JINSHAN, SHANGHAI TO: 215123 SUZHOU, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20141103 Address after: Suzhou City, Jiangsu Province, Suzhou Industrial Park, 215123 Street No. 218 Nano Technology Park building C4 Room 301 Applicant after: Suzhou Micro Diag Biomedicine Co., Ltd. Address before: 201507 Shanghai city Jinshan District Caojing town industry Road No. 80 Applicant before: SHANGHAI DUWEI MEDICAL TECHNOLOGY CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151124 Address after: Suzhou City, Jiangsu province 215000 Jinji Lake Avenue, Suzhou Industrial Park, No. 99 Suzhou West North Building 16 nm Patentee after: PUSHI HUAKANG JIANGSU MEDICAL TECHNOLOGY CO., LTD. Address before: Suzhou City, Jiangsu Province, Suzhou Industrial Park, 215123 Street No. 218 Nano Technology Park building C4 Room 301 Patentee before: Suzhou Micro Diag Biomedicine Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211206 Address after: 200120 all parts of floor 4, building 1, No. 271, Hong Kong Macao Road, pilot Free Trade Zone, Pudong New Area, Shanghai Patentee after: SHANGHAI LIANGRUN BIOMEDICAL TECHNOLOGY CO.,LTD. Address before: 215000 building 16, Northwest District, Suzhou nano City, 99 Jinjihu Avenue, Suzhou Industrial Park, Suzhou City, Jiangsu Province Patentee before: PUSHI HUAKANG JIANGSU MEDICAL TECHNOLOGY Co.,Ltd. |